Level A· Stronger Clinical EvidenceRandomized Controlled TrialEurope PMC

Autologous cells derived from different sources and administered using different regimens for 'no-option' critical lower limb ischaemia patients

Abdul Wahid SF., Ismail NA., Wan Jamaludin WF., Muhamad NA., Abdul Hamid MKA., Harunarashid H.

Randomized Controlled Trial with a reported sample of 359 on Ankle Injury, published in Cochrane Database Syst Rev (2018) — summary generated from the PubMed abstract.

Open my reading list
Level A· Stronger Clinical EvidenceEvidence level of this study

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Randomized Controlled Trial
Journal
Cochrane Database Syst Rev (2018)
Reported sample size
359
Source database
Europe PMC
PMID
30155883
PMCID
PMC6513643
DOI
10.1002/14651858.cd010747.pub2
Citations
30

Abstract (original English)

Background Revascularisation is the gold standard therapy for patients with critical limb ischaemia (CLI). In over 30% of patients who are not suitable for or have failed previous revascularisation therapy (the 'no-option' CLI patients), limb amputation is eventually unavoidable. Preliminary studies have reported encouraging outcomes with autologous cell-based therapy for the treatment of CLI in these 'no-option' patients. However, studies comparing the angiogenic potency and clinical effects of autologous cells derived from different sources have yielded limited data. Data regarding cell doses and routes of administration are also limited. Objectives To compare the efficacy and safety of autologous cells derived from different sources, prepared using different protocols, administered at different doses, and delivered via different routes for the treatment of 'no-option' CLI patients. Search methods The Cochrane Vascular Information Specialist (CIS) searched the Cochrane Vascular Specialised Register, the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE Ovid, Embase Ovid, the Cumulative Index to Nursing and Allied Health Literature (CINAHL), the Allied and Complementary Medicine Database (AMED), and trials registries (16 May 2018). Review authors searched PubMed until February 2017. Selection criteria We included randomised controlled trials (RCTs) involving 'n

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Relatively higher-quality human studies compared with other topics in this database, e.g. multiple RCTs or systematic reviews. This does not mean it is standard or approved care.

How we grade evidence
LegBone Marrow CellsHumansIschemiaLeg UlcerBone Marrow TransplantationMesenchymal Stem Cell TransplantationPeripheral Blood Stem Cell TransplantationInjections, Intra-ArterialInjections, Intramuscular

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research